肝硬化患者TIPS术后肠道菌群特征性改变及其与临床指标的相关性研究

李胜鹏; 肖续; 周安; 谢卓; 赵泳冰; 徐征国; 杨仕明; 唐波

doi:10.16016/j.2097-0927.202309122

您当前的位置：

首页 >

文章列表页 >

肝硬化患者TIPS术后肠道菌群特征性改变及其与临床指标的相关性研究

临床医学 | 更新时间：2026-01-09

- 肝硬化患者TIPS术后肠道菌群特征性改变及其与临床指标的相关性研究
- Changes in characteristics of gut microbiota and their correlation with clinical indicators in cirrhosis patients after transjugular intrahepatic portosystemic shunt
- 陆军军医大学学报 2024年46卷第12期页码：1425-1433
- 作者机构：
  
  400037 重庆，陆军军医大学第二附属医院消化内科
- 作者简介：
  
  [ 唐波，E-mail: botangxq@tmmu.edu.cn TANG Bo, E-mail: botangxq@tmmu.edu.cn
- 基金信息：
- DOI：10.16016/j.2097-0927.202309122
  中图分类号： R372;R446.112;R657.31
- 收稿：2023-09-20，
  
  修回：2023-10-18，
  
  纸质出版：2024-06-30
- 稿件说明：
移动端阅览
李胜鹏, 肖续, 周安, 等. 肝硬化患者TIPS术后肠道菌群特征性改变及其与临床指标的相关性研究[J]. 陆军军医大学学报, 2024,46(12):1425-1433.

Shengpeng LI, Xu XIAO, An ZHOU, et al. Changes in characteristics of gut microbiota and their correlation with clinical indicators in cirrhosis patients after transjugular intrahepatic portosystemic shunt[J]. Journal of Army Medical University, 2024, 46(12): 1425-1433.
李胜鹏, 肖续, 周安, 等. 肝硬化患者TIPS术后肠道菌群特征性改变及其与临床指标的相关性研究[J]. 陆军军医大学学报, 2024,46(12):1425-1433. DOI： 10.16016/j.2097-0927.202309122.

Shengpeng LI, Xu XIAO, An ZHOU, et al. Changes in characteristics of gut microbiota and their correlation with clinical indicators in cirrhosis patients after transjugular intrahepatic portosystemic shunt[J]. Journal of Army Medical University, 2024, 46(12): 1425-1433. DOI： 10.16016/j.2097-0927.202309122.

摘要

目的

比较既往行颈静脉肝内门体分流术(transjugular intrahepat portosystemic stent-shunt

TIPS)手术的肝硬化患者与未经TIPS手术的肝硬化患者的肠道菌群，探索在肝硬化患者中，TIPS手术与肠道菌群的关系，为基于肠道菌群干预改善肝硬化TIPS手术预后提供新思路。

方法

行TIPS手术的肝硬化患者为手术组，未经TIPS手术的肝硬化患者为对照组，收集患者大便标本行16S rRNA测序分析，并分析肠道菌群与临床指标相关性。

结果

两组患者在性别、年龄、体重指数(BMI)、病因等基线资料上均无显著差异(

0.05)，但临床血清学指标(如HGB，RBC，ALP，ALB，TBIL，PT，INR，APTT，UREA等)有显著差异(

＜0.05)。手术组与对照组相比，α多样性无统计学差异(

0.05)

β多样性差异明显(

＜0.01)

手术组

Bacteroides

(拟杆菌属)明显增多(

＜0.01)，而对照组

Bifidobacterium

(双歧杆菌属)明显增多(

＜0.05)。肠道菌群功能预测分析显示，手术组较对照组D-谷氨酰胺和D-谷氨酸代谢显著上升(

＜0.05)，次级胆汁酸生物合成(

＜0.05)也显著上升。临床指标

与菌群相关性分析中发现，总胆红素(TBIL)及直接胆红素(DBIL)与

Bacteroides

(拟杆菌属)、次级胆汁酸代谢通路显著相关。

结论

肝硬化TIPS术后患者肝硬化对照者相比，肠道菌群存在特征性改变，

Bacteroides

(拟杆菌属)可能参与胆汁酸代谢调控进而影响TIPS术后血胆红素水平升高。

Abstract

Objective

To compare the differences in gut microbiota between cirrhosis patients receiving transjugular intrahepatic portosystemic shunt (TIPS) and those not

and explore the relationship between TIPS surgery and gut microbiota in order to provide new ideas for improving the prognosis of cirrhosis patients after TIPS surgery based on gut microbiota.

Methods

Those who had received TIPS surgery previously were assigned into the operation group

and those without the surgery served as the control group. Their stool samples were collected for 16S rRNA sequencing

and the correlation between gut microbiota and clinical indicators was analyzed.

Results

There were no significant differences in gender

age

body mass index (BMI)

etiology and other baseline data between the 2 groups (

0.05)

but obvious differences were observed in clinical serological indicators between them

including INR

APTT

RBC and PT counts

and HGB

ALP

ALB

total bilirubin (TBIL)

and URE levels (

0.05). No statistical difference in alpha diversity was observed between the operation group and the control group (

0.05)

but beta diversity was obviously different (

0.01)

among which

Bacteroides

was increased in the operation group (

0.01) and

Bifidobacterium

was increased in the control group (

0.05). The function prediction analysis of gut microbiota showed that the metabolism of D-glutamine and D-glutamate (

0.05) and biosynthesis with secondary bile acids (

0.05) were up

-regulated in the operation group compared with the control group. Correlation analysis between clinical indicators and flora indicated that TBIL and direct bilirubin (DBIL) were significantly correlated with the metabolic pathways of

Bacteroides

and Secondary bile acids biosynthesis.

Conclusion

Characteristic changes in gut microbiota are found in cirrhosis patients with and without TIPS surgery.

Bacteroides

may be involved in the regulation of metabolism of bile acids and thus increase bilirubin level.

关键词

Keywords

references

GINES P, KRAG A, ABRALDES J G, et al . Liver cirrhosis[J ] . Lancet, 2021, 398(10308): 1359-1376. DOI: 10.1016/s0140-6736(21)01374-x.

LEE H L, LEE S W. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: advantages and pitfalls[J]. Clin Mol Hepatol, 2022, 28(2): 121-134. DOI: 10.3350/cmh.2021.0239.

PATIDAR K R, SYDNOR M, SANYAL A J. Transjugular intrahepatic portosystemic shunt[J]. Clin Liver Dis, 2014, 18(4): 853-876. DOI: 10.1016/j.cld.2014.07.006.

PFLUGHOEFT K, VERSALOVIC J. Human microbiome in health and disease[J]. Annu Rev Pathol. 2012;7: 99-122. doi: 10.1146/annurev-pathol-011811-132421.

GILL S R, POP M, DEBOY R T, et al . Metagenomic analysis of the human distal gut microbiome[J ] . Science, 2006, 312(5778): 1355-1359. DOI: 10.1126/science.1124234.

EL-SAYED A, ALEYA L, KAMEL M. Microbiota's role in health and diseases[J]. Environ Sci Pollut Res Int, 2021, 28(28): 36967-36983. DOI: 10.1007/s11356-021-14593-z.

SOLE C, GUILLY S, DA SILVA K, et al . Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis[J ] . Gastroenterology, 2021, 160(1): 206-218.e13. DOI: 10.1053/j.gastro.2020.08.054.

QIN N, YANG F L, LI A, et al . Alterations of the human gut microbiome in liver cirrhosis[J ] . Nature, 2014, 513(7516): 59-64. DOI: 10.1038/nature13568.

ACHARYA C, SAHINGUR S E, BAJAJ J S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis[J]. JCI Insight, 2017, 2(19): e94416. DOI: 10.1172/jci.insight.94416.

AHLUWALIA V, BETRAPALLY N S, HYLEMON P B, et al . Impaired gut-liver-brain axis in patients with cirrhosis[J ] . Sci Rep, 2016, 6(1): 1-11. DOI: 10.1038/srep26800.

BAJAJ J, KHORUTS A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis[J]. J Hepatol. 2020 May; 72(5): 1003-1027. doi: 10.1016/j.jhep.2020.01.017.

LUPP C, FINLAY B B. Intestinal microbiota[J]. Curr Biol, 2005, 15(7): R235-6. doi: 10.1016/j.cub.2005.03.032.

CHACON O, BERMUDEZ L E, BARLETTA R G. Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis [J ] . Annu Rev Microbiol, 2004, 58: 329-363. DOI: 10.1146/annurev.micro.58.030603.123726.

BACKHED F, LEY R E, SONNENBURG J L, et al . Host-bacterial mutualism in the human intestine[J ] . Science, 2005, 307(5717): 1915-1920. DOI: 10.1126/science.1104816.

CHEN Y, ZHOU J, WANG L. Role and mechanism of gut microbiota in human disease[J], Front Cell Infect Microbiol[J]. 2021 (11): 625913. doi: 10.3389/fcimb.2021.625913

BARKO P, MCMICHAEL M A, SWANSON K, et al . The gastrointestinal microbiome: a review[J ] . J Vet Intern Med, 2017, 32: 9-25. DOI: 10.1111/jvim.14875.

ARUMUGAM M, RAES J, PELLETIER E, et al . Enterotypes of the human gut microbiome[J ] . Nature, 2011, 473(7346): 174-180. DOI: 10.1038/nature09944.

STOJANOV S, BERLEC A, STRUKELJ B. The influence of probiotics on the firmicutes/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease[J]. Microorganisms, 2020, 8(11): 1715. DOI: 10.3390/microorganisms8111715.

LANKELMA J M, VAN VUGHT L A, BELZER C, et al . Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study[J ] . Intens Care Med, 2017, 43(1): 59-68. DOI: 10.1007/s00134-016-4613-z.

DE VOS W M, DE VOS E A. Role of the intestinal microbiome in health and disease: from correlation to causation[J]. Nutr Rev, 2012, 70(suppl_1): S45-S56. DOI: 10.1111/j.1753-4887.2012.00505.x.

LEY R E, TURNBAUGH P J, KLEIN S, et al . Human gut microbes associated with obesity[J ] . Nature, 2006, 444(7122): 1022-1023. DOI: 10.1038/4441022a.

PONZIANI F R, BHOORI S, CASTELLI C, et al . Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J ] . Hepatology, 2018, 69(1): 107-120. DOI: 10.1002/hep.30036.

GEDGAUDAS R, BAJAJ J S, SKIECEVICIENE J, et al . Circulating microbiome in patients with portal hypertension[J ] . Gut Microbes, 2022, 14(1): 2029674. DOI: 10.1080/19490976.2022.2 029674.

LIU J J, WU D C, AHMED A, et al . Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals[J ] . Curr Microbiol, 2012, 65(1): 7-13. DOI: 10.1007/s00284-012-0105-8.

HUANG L, YU Q, PENG H, et al . Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis[J ] . Medicine (Baltimore). 2022;101(51): e32335. doi: 10.1097/MD.0000000000032335.

EREG D, KOTLIROFF A, GADOTH N, et al . Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study[J ] . Nutrition. 2011, 27(2): 177-181. doi: 10.1016/j.nut.2010.01.006.Epub2010May10.

JIN R, BANTON S, TRAN V T, et al . Amino acid metabolism is altered in adolescents with nonalcoholic fatty liver disease—an untargeted, high resolution metabolomics study[J ] . J Pediatr, 2016, 172: 14-19.e5. DOI: 10.1016/j.jpeds.2016.01.026.

KROUPINA K, BEMEUR C, ROSE C. Amino acids, ammonia, and hepatic encephalopathy[J]. Anal Biochem. 2022(15);649: 114696. doi: 10.1016/j.ab.2022.114696

RIDLON J M, KANG D J, HYLEMON P B. Bile salt biotransformations by human intestinal bacteria[J]. J Lipid Res, 2006, 47(2): 241-259. DOI: 10.1194/jlr.r500013-jlr200.

RIDLON J M, KANG D J, HYLEMON P B, et al . Bile acids and the gut microbiome[J ] . Curr Opin Gastroenterol, 2014, 30(3): 332-338. DOI: 10.1097/MOG.0000000000000057.

TANG B, TANG L, LI S P, et al . Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy[J ] . Nat Commun, 2023, 14(1): 1-17. DOI: 10.1038/s41467-023-36981-4.

SUN L L, ZHANG Y, CAI J, et al . Bile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer[J ] . Nat Commun, 2023, 14(1): 755. DOI: 10.1038/s41467-023-36089-9..

SONG Z W, CAI Y Y, LAO X Z, et al . Taxonomic profiling and populational patterns of bacterial bile salt hydrolase ( BSH ) genes based on worldwide human gut microbiome[J ] . Microbiome, 2019, 7(1): 1-16. DOI: 10.1186/s40168-019-0628-3..

HIRANO S, MASUDA N. Enhancement of the 7 alpha-dehydroxylase activity of a gram-positive intestinal anaerobe by Bacteroides and its significance in the 7-dehydroxyl ation of ursodeoxycholic acid[J ] . J Lipid Res, 1982, 23(8): 1152-1158.

BERNSTEIN C, BERNSTEIN H, GAREWAL H, et al . A bile acid-induced apoptosis assay for colon cancer risk and associatedquality control studies[J ] . Cancer Res, 1999, 59(10): 2353-2357.

ZENG H W, SAFRATOWICH B D, CHENG W H, et al . Deoxycholic acid modulates cell-junction gene expression and increases intestinal barrier dysfunction[J ] . Molecules, 2022, 27(3): 723. DOI: 10.3390/molecules27030723.

CAMILLERI M. Bile acid detergency: permeability, inflammation, and effects of sulfation[J]. Am J Physiol Gastrointest Liver Physiol, 2022, 322(5): G480-G488. DOI: 10.1152/ajpgi.00011.2022.

浏览量

232

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

小檗碱调节肠道菌群改善小鼠药物性肝损伤

胆囊切除术与肠道菌群组成及其功能变化关系的研究

藏汉不同体质指数人群肠道菌群与生化指标的差异研究

基于多中心数据探索肠道菌群对结直肠息肉的预测作用

胆汁淤积性肝病患者肠道菌群特征及其临床相关性研究